Khow Kareeann Sok Fun, Yong Tuck Yean
Department of Aged and Extended Care, The Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia.
J Bone Miner Metab. 2015 May;33(3):355-8. doi: 10.1007/s00774-014-0606-6. Epub 2014 Jul 5.
Atypical fractures of the femur (AFF) have been reported in the literature at an increasing rate over the past decade, especially in patients who have been on prolonged courses of bisphosphonates. However, there have only been a few reported cases of AFF in those treated with other antiresorptive medications. In this case report, a 72-year-old woman with chronic obstructive pulmonary disease and osteoporosis presented with an atraumatic right femoral fracture in the setting of denosumab use. In contrast with other reports, this patient had received bisphosphonate therapy for a short duration before the switch to denosumab. While causality between the fracture and denosumab use cannot be established in this case, there is a growing number of reports of a similar association. Ongoing vigilance is required to determine whether denosumab is associated with or potentially a cause of AFF.
在过去十年中,文献报道的非典型股骨骨折(AFF)发生率呈上升趋势,尤其是在长期使用双膦酸盐类药物的患者中。然而,在接受其他抗吸收药物治疗的患者中,仅报告了少数AFF病例。在本病例报告中,一名患有慢性阻塞性肺疾病和骨质疏松症的72岁女性在使用地诺单抗的情况下出现了无创伤性右股骨骨折。与其他报告不同的是,该患者在改用 地诺单抗之前接受双膦酸盐治疗的时间较短。虽然在本病例中无法确定骨折与使用地诺单抗之间的因果关系,但越来越多的报告表明存在类似关联。需要持续保持警惕,以确定地诺单抗是否与AFF有关联或可能是其病因。